

Conjugate Meningococcal Vaccine and Oral Typhoid Vaccine

Joan Ingram







































Meningococcal vaccine

- Menactra: New meningococcal vaccine
- Conjugate vaccine
 - Previous (non B) vaccines were polyscaccharide
 - Menomune and Mencevax ACWY
- In conjugate vaccines the poylsaccharide is conjugated to a protein carrier such as tetanus toxoid or diphtheria toxoid




































How do polysaccharide and conjugate vaccines differ?














































How polysaccharide vaccines work



 Polysaccharides stimulate B cells by cross-linking the B-cell receptor (BCR)






































How polysaccharide vaccines work



- Drives the production of immunoglobulins
- No production of new memory B cells
- Depletion of the memory B-cell pool so subsequent immune responses are decreased








































How conjugate vaccines work



- The carrier protein from protein-polysaccharide conjugate vaccines is processed by the polysaccharide-specific B cell
- Peptides are presented to carrier-peptide-specific T cells, resulting in T-cell help for the production of both plasma cells and memory B cells








































How conjugate vaccines work









































Conjugate vaccines

- Induce T cell dependent response
 - Occurs from early infancy
 - More effective in younger infants
 - First dose primes immune system to stronger response to a booster dose
- Reduce nasopharyngeal carriage of N.meningitidis
 - reduced community transmission -"herd effect"
 - Seen with introduction of
 - Conjugate H. influenzae (Hib)
 - Conjugate pneumococcal vaccines (e.g. Prevenar)
 - Meningococcal serogroup C conjugate vaccine in UK, Netherlands




































Invasive pneumococcal disease (PCV7 serotypes) in non-immunised adults > 18 years






FIGURE 1. Incidence of meningococcal C disease in the Netherlands, by age group and year.

- For 2 to 55 years, single dose
- NZ: "need or timing of booster not yet determined"
- US:-If 2-6 when vaccinated boost after 3 years
 - If >7 years boost after 5 years
- Not licensed in NZ for < 2 years of age
- American recommendations:
 - 2-8 months (off label): 2 doses 1 month apart, booster at 12 months
 - 9- 23 months: 2 doses 3 months apart, boost at 3 years
 - Asplenic, complement deficiencies, HIV: 2 doses 2 months apart







































Responses 28 days after vaccination in 2 to 3 year olds

		Menactra vaccine	Menomune
Serogroup			
A	% titre ≥ 1:8	73	64
	GMT	10	10
С	% titre ≥ 1:8	63	38
	GMT	27	11
Υ	% titre ≥ 1:8	88	73
	GMT	51	18
W-135	% titre ≥ 1:8	63	33
	GMT	15	5

GMT = Geometric mean titre







































Side effects

- Serious adverse events in 6 months following Menactra at same rate as after Menomune (1.3%)
- Local reactions more frequent than after Menomune




































Frequency of adverse events in 11 to 18 year olds within 7 days of vaccination





Guillian –Barre Syndrome (GBS)

- Has been reported following Menactra
- Multi-site retrospective study involving over 12 million adolescents of whom 1.4m received Menactra found no evidence of increased risk
- Previous GBS is a contraindication





































Who to give it to?

- Travellers to meningitis belt of Africa
 - Particularly if during dry season, health care workers, infants and children
- Those doing the Hajj pilgrimage (meningococcal vaccine in past 3 years is required)
- Consider for adolescents and young adults planning to stay in hostels/ overcrowded conditions
- (Routine vaccine in US for 11-12 year olds with a booster at 16 years)










































Figure 4 Meningococcal vaccination decision algorithm for travelers. 4V = quadrivalent; KSA = Kingdom of Saudi Arabia; UK = United Kingdom; US = United States; VFRs = visiting friends and relatives.



Oral typhoid vaccine

- Vivotif now available again
- Live attenuated vaccine containing Ty21a strain which is deficient in an enzyme so it can't metabolise galactose
- Galactose is present in the gut so vaccine bacteria accumulate galactose and lyse- not detected in stools 3 days after ingestion










































- No studies in travellers
- In endemic areas 50 to 80%
- May provide some protection against paratyphi









































Dosage/ administration

- Keep refrigerated
- 3 doses on alternate days e.g. 1,3 and 5 for those above 6 years of age
- Swallow whole, not chewed
- One hour before a meal with cold or lukewarm drink
- Complete 1 week before potential exposure
- Optimal booster timing unclear: 3 years
- In America they have a 4 dose primary series and boost at 5 years





































Contraindication and precautions

- Immunodeficiency including HIV, drug induced
- Acute febrile illness or GI illness
- Pregnancy
- Concurrent antibiotics (wait > 72 hours after stopping antibiotic)
- Optimally wait 3 days before starting antimalarials but mefloquine, malarone & chloroquine probably Ok





































Adverse effects

 Generally mild- constipation, abdominal cramps, diarrhoea, nausea, vomiting, anorexia, fever, headache, rash





































